Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer.

Saved in:
Bibliographic Details
Title: Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer.
Authors: Keyl J; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany.; Institute of Pathology, University Hospital Essen, Essen, Germany., Hosch R; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany., Hörst F; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany.; Cancer Research Center Cologne Essen (CCCE), West German Cancer Center Essen, University Hospital Essen, Essen, Germany., Keyl P; BIFOLD - Berlin Institute for the Foundations of Learning and Data, Berlin, Germany.; Institute of Pathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Berlin, Berlin, Germany.; Institute of Pathology, Ludwig-Maximilians-University Munich, Munich, Germany.; Bavarian Cancer Research Center (BZKF), Munich, Germany., Dada A; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany., Haubold J; Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany., Straus J; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany.; Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany., Egger J; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany., Stahler A; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Kurreck A; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Ballhausen A; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Stintzing S; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Fruehauf S; Dr Hancken Hospital, Stade, Germany., Müller L; Onkologie UnterEms, Leer, Germany., Alig AHS; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Trarbach T; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; Reha-Zentrum am Meer, Bad Zwischenahn, Germany., Hartmann S; Institute of Pathology, University Hospital Essen, Essen, Germany., Nensa F; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany.; Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany., Kleesiek J; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany., Kasper S; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; National Center for Tumor Diseases (NCT), NCT West, Essen, Germany.; German Cancer Consortium (DKTK), Partner Site Essen, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Schuler M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; National Center for Tumor Diseases (NCT), NCT West, Essen, Germany.; German Cancer Consortium (DKTK), Partner Site Essen, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Modest DP; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Mar 02; Vol. 32 (5), pp. 938-946.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-25-3080